BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 ...
Led by Professor Takaaki Abe at Tohoku University Graduate School of Medicine, the team discovered that a medicine usually ...
Progenics could receive $20 million in milestones. Ono Pharmaceutical is paying $15 million for rights to develop Progenics Pharmaceuticals’ opioid-induced constipation drug, Relistor®, in Japan.
Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...
Sweden's Albireo has reached a licensing deal with a Japanese drugmaker, giving Ajinomoto Pharmaceuticals the rights to develop and market a constipation drug in Japan, South Korea, Thailand, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback